A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry

被引:73
作者
Tang, Huaidong [1 ]
Mayersohn, Michael [1 ]
机构
[1] Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA
关键词
allometric scaling; vertical allometry; clearance; protein binding; C logP;
D O I
10.1002/jps.20481
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Allometrically scaled data sets (138 compounds) used for predicting human clearance were obtained from the literature. Our analyses of these data have led to four observations. (1) The current data do not provide strong evidence that systemic clearance (CLs; n = 102) is more predictable than apparent oral clearance (CLpo; n = 24), but caution needs to be applied because of potential CLpo prediction error caused by differences in bioavailability across species. (2) CL, of proteins (n = 10) can be more accurately predicted than that of non-protein chemicals (n = 102). (3) CL, is more predictable for compounds eliminated by renal or biliary excretion (n = 33) than by metabolism (n = 57). (4) CL predictability for hepatically eliminated compounds followed the order: high CL (n = 11) > intermediate CL (n = 17) > low CL (n = 29). All examples of large vertical allometry (% error of prediction greater than 1000%) occurred only when predicting human CLs of drugs having very low CLs. A qualitative analysis revealed the application of two potential rules for predicting the occurrence of large vertical allometry: (1) ratio of unbound fraction of drug in plasma (f(u)) between rats and humans greater than 5; (2) C logP greater than 2. Metabolic elimination could also serve as an additional indicator for expecting large vertical allometry. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:1783 / 1799
页数:17
相关论文
共 162 条
[21]   CORRELATION OF UNBOUND PLASMA CLEARANCES OF 15 EXTENSIVELY METABOLIZED DRUGS BETWEEN HUMANS AND RATS [J].
CHIOU, WL ;
HSU, FH .
PHARMACEUTICAL RESEARCH, 1988, 5 (10) :668-672
[22]   INTERSPECIES PHARMACOKINETIC SCALING OF SCH-34343 [J].
CHUNG, M ;
RADWANSKI, E ;
LOEBENBERG, D ;
LIN, CC ;
ODEN, E ;
SYMCHOWICZ, S ;
GURAL, RP ;
MILLER, GH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :227-233
[23]   METABOLISM AND EXCRETION OF A CHROMONE CARBOXYLIC-ACID (FPL-52757) IN VARIOUS ANIMAL SPECIES [J].
CLARK, B ;
SMITH, DA ;
EASON, CT ;
PARKE, DV .
XENOBIOTICA, 1982, 12 (03) :147-153
[24]   Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates [J].
Coassolo, P ;
Fischli, W ;
Clozel, JP ;
Chou, RC .
XENOBIOTICA, 1996, 26 (03) :333-345
[25]   COMPARISON OF THE DISPOSITION AND OF THE METABOLIC PATTERN OF REBOXETINE, A NEW ANTIDEPRESSANT, IN THE RAT, DOG, MONKEY AND MAN [J].
COCCHIARA, G ;
BATTAGLIA, R ;
PEVARELLO, P ;
BENEDETTI, MS .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1991, 16 (03) :231-239
[26]   METABOLISM OF ACTISOMIDE IN THE DOG, MONKEY AND MAN - A NOVEL REARRANGEMENT OF NORMAL-DEALKYLATED METABOLITES [J].
COOK, CS ;
ROZEK, LF ;
HRIBAR, J ;
SCHOENHARD, GL ;
KARIM, A .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1992, 17 (02) :145-154
[27]   Mixed effect modeling of sumatriptan pharmacokinetics during drug development .1. Interspecies allometric scaling [J].
Cosson, VF ;
Fuseau, E ;
Efthymiopoulos, C ;
Bye, A .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1997, 25 (02) :149-167
[28]   INTERSPECIES SCALING OF TEBUFELONE PHARMACOKINETIC DATA AND APPLICATION TO PRECLINICAL TOXICOLOGY [J].
CRUZE, CA ;
KELM, GR ;
MEREDITH, MP .
PHARMACEUTICAL RESEARCH, 1995, 12 (06) :895-901
[29]   DISPOSITION OF MINAPRINE IN ANIMALS AND IN HUMAN EXTENSIVE AND LIMITED DEBRISOQUINE HYDROXYLATORS [J].
DAVI, H ;
BONNET, JM ;
BERGER, Y .
XENOBIOTICA, 1992, 22 (02) :171-184
[30]  
DUSTERBERG B, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1187